HBsAg蛋白疫苗对HBV感染免疫耐受患者的治疗作用

Therapeutic effects of HBsAg protein vaccine on hepatitis B viral carriers with immune tolerance

目的:探索乙肝治疗性疫苗(即HBsAg蛋白疫苗,由乙肝疫苗60μg、卡介苗素1mg、花生油水乳化剂0·1ml组成,混合使用),对慢性乙型肝炎免疫耐受患者的治疗效果。方法:选择120例HBsAg+、HBeAg+、抗-HBc+、HBVDNA+,ALT、AST正常者,垂直传播、水平传播各半,分3组:治疗1组(垂直传播)40例,治疗2组(水平传播)40例,对照组(水平垂直各半)40例。给药方法:HBsAg蛋白疫苗每3周双侧三角肌注射1次共12个月,HBIG200IU每3周1针肌注,共12个月。结果:治疗1组:HBeAg转阴率为50%,HBVDNA阴转率为57·5%;治疗2组:HBeAg阴转率50%,HBVDNA阴转率57·5%;对照组HBeAg转阴率为5%,HBVDNA阴转率为20%。结论:HBsAg蛋白疫苗对慢性乙型肝炎免疫耐受有较好的治疗作用,可进一步研究试用。

Objective： To investigate the therapeutic effects of HBsAg protein vaccine on hepatitis B viral carriers. Methods：One hundred and twenty hepatitis B viral carriers with positive HBeAg, anti-HBc, HBV DNA and normal ALT and AST were selected as study subjects, of whom 60 were vertically infected and 60 horizontally infected, Forty of each group were treated with intramuscular injection of HBsAg protein vaccine 30μg and HBIG 200 IU once 3 weeks for 12 months while theother 20 were treated with levamisole as control. Results： Compared with the control group, the P/co value of significantly decreased （P〈0.001） in the treatment group, with HBeAg and HBV DNA became negative in 50% vs, 5% and 57.5 % vs, 20 % of them, respectively. Conclusion： HBsAg protein vaccine is shown to be an efficiently used in hepatitis B viral carriers with immune tolerance.